Clinical Report: Pilot Randomized Trial of Amygdala Neurofeedback Added to Residential DBT

Overview

This pilot randomized study was designed to assess whether real-time fMRI amygdala neurofeedback (amy-NF) added to residential Dialectical Behavior Therapy (DBT) reduces daily-life instability of negative affect more than DBT alone in adults with BPD and persistent symptoms. It included a treatment-as-usual control arm and planned follow-up assessments at 3 and 6 months; the supplied article text describes the rationale and methods but does not provide trial results.

Background

BPD is associated with emotional instability and impulsivity, as well as amygdala hyperactivity and altered connectivity in fronto-limbic networks. DBT is an evidence-based treatment reported to reduce amygdala hyperactivation and emotional symptoms, although the source notes that many patients experience only partial remission and persistent impairment. Amy-NF provides real-time information about amygdala activity to support its modulation, and earlier pilot studies in BPD reported reductions in amygdala activation and symptom severity but lacked control groups and long-term follow-up. The present study was designed to examine amy-NF as an addition to DBT, with daily-life negative-affect instability as its primary endpoint.

Data Highlights

Key Findings

• The study was designed to test the added value of amy-NF during residential DBT for adults with BPD and relatively high symptom severity at the 6-week midpoint.
• Participants were eligible at a BSL-23 score of at least 1.5; the threshold was initially 1.87 and was lowered during the study to facilitate recruitment.
• The primary endpoint was instability of negative affect in daily life, measured with Ecological Momentary Assessment.
• Self-report measures and neural outcomes were designated as secondary endpoints.
• The design included a treatment-as-usual control arm and assessments at 3 and 6 months, addressing limitations identified in earlier BPD amy-NF investigations.
• The authors characterized the study as preliminary evidence-generating because of the sample size; the supplied text does not report efficacy findings.

Clinical Implications

The supplied material describes a pilot investigation and does not provide results that establish whether adding amy-NF improves outcomes over DBT alone. The study’s findings, when available, would need to be interpreted in light of its preliminary scope and its specific population: adults with persistent symptoms midway through a residential DBT program.

Conclusion

This trial was designed to evaluate amy-NF as an adjunct to residential DBT, using daily-life affective instability as its primary outcome and including longer-term follow-up. The provided source material contains no outcome results, so it does not support conclusions about comparative efficacy.

Related Resources & Content

1. American Psychiatric Association, Psychiatry.org, 2024 — Updated Borderline Personality Disorder Guideline
2. Cochrane, 2020 — Psychological therapies for people with borderline personality disorder
3. BMC Psychiatry, 2025 — A randomised controlled trial of amygdala fMRI-neurofeedback versus sham-feedback in borderline-personality disorder: systematic literature review and introduction to the BrainSTEADy trial
4. Frontiers in Psychiatry — Evaluation of a Parent-Exclusive DBT Skills Group within Public Mental Health Services: A Pilot Implementation Analysis
5. Frontiers in Psychiatry — Enhancing psychiatry education: effectiveness of a psychodynamic psychotherapy module for borderline personality disorder for psychiatry residents
6. Frontiers in Psychiatry — Efficacy of psychological interventions for adolescents with borderline personality disorder: a systematic review and meta-analysis
7. BMC Psychiatry (Springer) — Impact of Enhanced Intermittent Theta Burst Stimulation on Depressive Symptoms and Cognitive Abilities in Adolescents with Bipolar Disorder
8. American Psychiatric Association Publishes Updated Practice Guideline on the Treatment of Borderline Personality Disorder
9. Psychological therapies for people with borderline personality disorder
10. A randomised controlled trial of amygdala fMRI-neurofeedback versus sham-feedback in borderline-personality disorder – systematic literature review and introduction to the BrainSTEADy trial
11. Psychiatry.org - American Psychiatric Association Publishes Updated Practice Guideline on the Treatment of Borderlin
12. Psychological therapies for people with borderline personality disorder | Cochrane
13. A randomised controlled trial of amygdala fMRI-neurofeedback versus sham-feedback in borderline-personality disorder – systematic literature review and introduction to the BrainSTEADy trial | BMC Psychiatry | Springer Nature Link